On May 1, 2006 all the Chemistry Department imaging programs transferred to the BNL Medical Department, however all programmatic material herein remains unchanged.

New Development of Norepinephrine Transporter Radioligands for PET Studies of Substance Abuse, Depression and ADHD

   Positron Emission Tomography (PET) imaging has been recognized as a powerful tool in clinical psychopharmacology and drug development. Three monoamine neurotransmitters, norepinephrine (NE), dopamine (DA) and serotonin (SER), are involved in regulating many Central Nervous System functions such as attention, arousal, cognition and mood. Research on DA and SER systems related to substance abuse and depression has benefited from the availability of suitable radioligands. The norepinephrine transporter (NET) has long been recognized in relation to the pathophysiology and treatment of ADHD (Attention Deficit Hyperactivity Disorder), substance abuse and depressive disorders. However, brain imaging of NET has been hampered by the lack of suitable radioligands. Given the availability of ligands for both DA and SER transporters (DAT and SERT) at BNL, the development of suitable NET radioligands would provide an ideal combination for examining the current hypotheses on the pathophysiology and treatment of various CNS disorders resulting from the dysfunction of these three neurotransmitters.

Transaxial PET images obtained at baseline and after pretreatment with nisoxetine after injection of (S,S)-[11C]MRB.

This program is supported by a Laboratory-Directed Research and Development Grant (LDRD). We acknowledge Brookhaven National Laboratory for this support.

 Learn more about the Brookhaven Center for Translational Neuroimaging.

Top of Page

Last Modified: June 28, 2012